Navigation Links
Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
Date:9/9/2008

SAN FRANCISCO, Sept. 9 /PRNewswire/ -- Epiphany Biosciences, Inc. today announced that a Phase 2b dose-ranging study to evaluate the safety, efficacy, and tolerability of the company's lead compound, valomaciclovir (EPB-348) in patients with acute herpes zoster infection (shingles), will continue as originally designed following an interim analysis.

Fred Volinsky, MD, Epiphany's CEO said, "We are pleased with the progress of this clinical trial and look forward to the final data. If successful, valomaciclovir will mark an advance in the treatment of herpes zoster which affects more than two million people annually around the globe. As the world population ages, it is expected that the incidence of this disease will grow significantly, especially in lieu of the lackluster response to vaccines in this area. We look to valomaciclovir to enhance the treatment experience by being the first once-daily therapy for shingles." The Phase 2b study is being conducted at sites throughout North America and uses an active comparator, valacyclovir. Outcomes assessed include various efficacy parameters including time to vesicular resolution and safety data collection.

In addition to the Phase 2b zoster study, valomaciclovir will also be studied in a separate Phase 2 clinical trial as a therapy in managing the most severe sequelae of a herpes-zoster infection, post-herpetic neuralgia or PHN. "The spectrum of disease caused by herpes viruses is underappreciated but a disease like shingles can have a profound impact on the quality-of-life of patients, many times leading to severe pain syndromes that could have a viral etiology. We look forward to examining the clinical utility of valomaciclovir in multiple conditions associated with herpes viruses and plan to maximize the broad-acting antiviral profile of this drug," reported Brian Murphy, MD, Chief Medical Officer of Epiphany.

In addition to the studies directed at herpes zoster, valomaciclovir is also bein
'/>"/>

SOURCE Epiphany Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
2. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
3. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announced ... Tuesday, August 4 at 11:30 a.m. Eastern Time to ... on pipeline and business progress.  Interested ... or access the webcast at www.isispharm.com .  A ... at the same address. ABOUT ISIS PHARMACEUTICALS, ...
(Date:7/28/2015)... Calif. , July 28, 2015 ... that it will report its second quarter 2015 financial ... 2015.  Rigel senior management will follow the announcement ... 4:30pm Eastern Time (1:30pm Pacific Time) to discuss ... the live conference call by dialing 855-892-1489 (domestic) ...
(Date:7/27/2015)... , July 28, 2015 CTI BioPharma ... plans to report its second quarter 2015 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call 3Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results 2CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2
(Date:7/28/2015)... ... July 28, 2015 , ... ... Invisible Aligner System to its online product offerings, giving its customers the ... model and cloud-based technology, SmileCareClub allows patients to get quality, remote invisible aligner ...
(Date:7/28/2015)... ... 28, 2015 , ... A new Taiwanese study suggests that ... in the general population. Surviving Mesothelioma has just posted an article detailing the ... Taiwan’s National Health Research Institutes and three Taiwanese universities evaluated the health records ...
(Date:7/28/2015)... ... July 28, 2015 , ... Fertility specialist Dr. Lisa ... Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty ... esteemed colleagues and peers in the metro area as one of the most respected ...
(Date:7/28/2015)... Angeles, CA (PRWEB) , ... July 28, 2015 ... ... Sports entitled "A Breakdown of Mets' David Wright's Spinal Stenosis Injury" discussed ... the field. Wright’s spinal stenosis is acquired lumbar stenosis, brought on by degenerative ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... line has won the 2015 NCW Eco-Excellence Award for the Nutrition Beverage category. ... pet lifestyle industries and elevate companies that stand out for their social and ...
Breaking Medicine News(10 mins):Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 2Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 3Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 2Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 3Health News:Coco Libre Wins 2015 NCW Eco-Excellence Award 2
... since November// 2005. ,Test samples sent to a laboratory ... suspected a case of bird flu, in sick and ... The immediate measures taken were the closure of the Kuwaiti zoo; ... falcon farms and bird clinics. Export and import of birds and ...
... a huge success and President Gloria Macapagal-Arroyo wants the ... ,On Thursday, at a round table discussion in Malacanang, ... drugstore willing to sell medicine at cheaper prices. ... Trading Corporation to purchase these cheap medicines is because ...
... ill Saturday after drinking water from a river contaminated by ... people down with poisoning to 48. // ,"The ... make the river water fit for human consumption and check ... of the state's public health engineering (PHE) department. ...
... suspected of having contracted AIDS was allegedly beaten to death ... 30, a resident of Keutunga village in Puri district, 50 ... she was an AIDS patient, police officer Guruprasad Shib Sankar ... Friday night but came to light only after her father ...
... A new way to select patients for further testing ... predisposes people to developing colorectal cancer at a young ... the Journal of the National Cancer Institute. ... (HNPCC), is caused by mutations in DNA mismatch repair ...
... at loggerheads with the pharmaceutical industry over its decision ... ,While Thailand argues it will make cheap generic drugs ... that the plan undermines patent law and discourages foreign ... Bangkok CEO of US drug firm, Merck Sharp and ...
Cached Medicine News:Health News:Drug Companies Hit Out at Thai Generic Drug Scheme 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: